RCKT Rocket Corp Earnings per share trend in current year
The absence of stable cash flows due to the clinical trial stage makes the financial profile of Rocket Pharmaceuticals (RCKT) dependent on regulatory verdicts. The 12-month EPS growth rate demonstrates profit dynamics, where 91.90 is recorded as the baseline value. High expert confidence bolsters the commercialization potential of ex vivo therapy for treating rare blood and heart pathologies, ensuring high future margins.
Analytical breakdowns and data insights for company Rocket Pharmaceuticals (RCKT)
- stock price and consensus target price:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Rocket Pharmaceuticals|RCKT - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio rocketpharma.com|RCKT - Company Aggregate Debts|Debts to Book Capitalization Rocket Corp|RCKT - Company Long-Term Debts|Company Current Liabilities Rocket Pharmaceuticals|Immediate Liquidity rocketpharma.com
- net income and valuation multiples indicators:
RCKT - Net Income|Projected Future Earnings Rocket Pharmaceuticals|RCKT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Rocket Corp|RCKT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Rocket Corp|RCKT - Operating profit EBITDA|Net earnings per share for the last 12 months Rocket Pharmaceuticals|RCKT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth rocketpharma.com|RCKT - Earnings per share growth in current year|Net earnings per share growth forecast for next year Rocket Pharmaceuticals
- sales volume and revenue information:
Fundamental valuation:Rocket Pharmaceuticals
Effective management of gene therapy development at Rocket Pharmaceuticals (RCKT) accelerates drug commercialization, which directly impacts the issuer's financial stability. The annual EPS change scale reflects the dynamics of earnings per share accounting for the cost of borrowed capital, helping investors assess multiple compression and debt service risks for this speculative asset amid high key interest rates.
Direct competitors
Tempus Labs - Earnings per share increase in current year|Earnings per share growth in current year Qiagen Group|Isis Pharmaceuticals - Earnings per share trend in current year|Earnings growth in current year RGEN|RNA (aviditybiosciences.com) - Earnings per share increase in current year|Earnings growth in current year CRSP (CRISPR Therapeutics)|Earnings growth in current year GeneDx Holdings WGS|RARE - Earnings per share growth in current year|Earnings per share increase in current year BEAM (Beam Tx)|Sarepta Therapeutics, Inc. (SRPT) - Earnings per share growth in current year|Net earnings per share growth this year twistbioscience.com|TXG (10x Genomics) - Earnings growth in current year|Earnings growth in current year Intellia Therapeutics Inc|Earnings growth in current year STOK|Net earnings per share growth this year BioLife BLFS|Earnings growth in current year WVE (Wave Life Sciences)|mazetx.com (MAZE) - Earnings per share growth rate in current year|SION: Net earnings per share growth this year|PRME - Earnings growth in current year|TSHA (Taysha) - Net earnings per share growth this year|QURE: Net earnings per one share growth for the current year|MGTX (MeiraGTx Holdings plc) - Earnings growth in current year|regenxbio.com (RGNX) - Expected net earnings per share growth this year|Earnings growth in current year SLDB|Net earnings per share growth this year Ocugen Inc OCGN|Earnings growth in current year PACB (Pacific Biosciences of California)|Earnings growth in current year Benitec Corp BNTC|DSGN - Earnings per share growth in current year|FDMT: Earnings per share growth in current year|lexeotx.com (LXEO) - Earnings per share growth in current year|KRRO - Expected net earnings per share growth this year|Earnings per share growth in current year Editas|SLN: Earnings per share increase in current year|Earnings growth in current year PRQR|Net earnings per share growth this year codexis.com CDXS|Earnings per share growth in current year Sangamo Therapeutics, Inc. SGMO|Earnings growth in current year Nautilus Biotechnology, Inc. NAUT|MGX: Net earnings per share growth this year|precisionbiosciences.com - Net earnings per one share growth for the current year|GBIO: Earnings growth in current year|Earnings per share growth this year BOLD|Earnings per share growth in current year Exicure Inc.|Earnings per share growth this year IMNN (Celsion Corporation)|Earnings growth in current year PHIO|Earnings growth in current year mustangbio.com (MBIO)|Earnings per share growth in current year TransCode Therapeutics, Inc. RNAZ|Earnings per share increase in current year BNGO|APDN - Earnings per share growth in current year|Earnings per share growth rate in current year bluebird bio Inc.|IPA: Earnings growth in current year|Net earnings per share growth this year Omega Therapeutics Corp|Earnings per share growth in current year Singular Genomics Systems|Earnings growth in current year regulusrx.com|Earnings growth in current year SYRS|TBIO - Earnings per share growth rate in current year|TRACON - Net earnings per share growth this year|Net earnings per one share growth for the current year UBX (Unity Biotechnology, Inc)
